# Adults who have HIV lost fat around organs inside the belly > Tesamorelin | Growth Hormone Axis research peptides — Growth Hormone Axis research peptides act on linked hormones. Tesamorelin reduced deep belly fat in adults who have HIV; general weight loss remains unproven. **03 / FAT IN ADULTS WITH HIV** Scans measured fat inside the belly and in the liver. Blood tests checked linked growth hormones, called an axis. Those results don’t predict your weight loss. ## The simple finding is less fat around belly organs in specific patients Scans found less fat around organs inside the belly. Tesamorelin trials mainly involved adults who have HIV and excess fat there. The drug has prescription approval for that particular fat problem. The approval doesn't cover everyone who wants to lose weight. Tesamorelin prompts the gland beneath the brain to send growth hormone into blood. Another hormone made by the liver helps tissues grow. Scientists checked blood hormones as well as changes in fat. A bigger blood rise doesn't establish a bigger fat loss for you. Scans measured the area of deep belly fat and checked liver fat. Other tests weighed tissue apart from fat, including muscle and bone. Trials compared treated patients with patients who didn't receive tesamorelin. That comparison helps identify changes due to the drug rather than other causes. Those fat trials provide clearer patient results than CJC-1295 or ipamorelin blood studies. The results still belong to the patients with HIV who took part and had excess fat around their internal organs, so the findings don't prove general weight loss or benefits for aging. Your own health and fat problem may differ from the patients' condition. ## The approved use and the liver review answer different questions Tesamorelin copies forty-four amino acids, the tiny joined pieces that make the natural hormone. The copied hormone tells the gland to send growth hormone into blood. Scientists changed the copy's end so the blood breaks the drug down more slowly. The drug can therefore work longer than the unchanged natural hormone. Two thousand eighteen: a National Institutes of Health review described its liver safety [13]. The review records United States approval in 2010 for excess fat inside the belly in adults who have HIV. That use doesn't extend to weight loss in people with a different fat problem. The review judged tesamorelin unlikely to cause liver injury that makes someone ill. The review found no cases of liver injury attributed to the drug. That finding concerns the liver, rather than every possible side effect. Favorable liver findings cannot guarantee safety in every person. ## Thirteen healthy men had higher blood hormones in a short study Tesamorelin makes the gland beneath the brain release growth hormone in bursts. The liver responds with more IGF-1, a hormone that helps tissues grow. Both hormones affect how the body uses and stores fat. Blood tests alone cannot establish how much fat someone lost. Two thousand eleven: thirteen healthy men took part in a two-week study [15]. Average overnight growth hormone rose, but that blood result didn't measure weight loss. IGF-1 rose by 181 micrograms per liter; a microgram is a millionth of a gram. The amount describes hormone in blood, rather than the percent rise. Without the starting blood reading, that amount cannot tell you how large the rise was. Scientists also tested sugar before breakfast and the body's response to insulin. The differences were too uncertain to show a clear treatment effect on sugar. Longer trials checked fat in adults who have HIV [14][16], while the short study couldn't rule out a sugar problem for you. ## Deep belly fat fell during treatment and returned after stopping 2026: a review brought together five trials in adults who have HIV and unusual fat buildup [12]. Treated patients had less fat around belly organs than the comparison patients. The scans showed a smaller area of that internal fat. The result describes an average difference between the groups, so your own change could be larger or smaller, and the study doesn't promise that every treated patient lost the same amount. The review also found less fat across the trunk, meaning the torso rather than just the fat around internal organs. Treated patients had lower liver fat readings than comparison patients. Tissue apart from fat weighed more, including muscle, bone and other tissue. Those different changes don't establish a general fall in body weight. Two thousand fourteen: fifty adults who have HIV taking HIV medicines joined a six-month trial [14]. Deep belly fat area fell by 42 square centimeters more with treatment than in the comparison group. Liver scans also showed a greater fall in fat with treatment. That liver finding concerns a different kind of fat from the belly finding. Two thousand eight: adults who have HIV had an eighteen-percent fall in deep belly fat [16]. That means the scanned fat area fell by that share of its starting area. The reduction lasted through fifty-two weeks while treatment continued. The fat built up again after treatment stopped. Average sugar changes didn't concern the researchers in that trial. That average doesn't establish everyone's sugar stayed safe. The trials found less internal fat in those adults. General weight loss and lasting loss after stopping remain unproven. ## Years of use leave questions about sugar and tissue growth The trials measured fat changes rather than collecting personal reports of how users felt. **A personal report hasn't been checked by comparing treated and untreated people and isn't a trial finding.** The available papers don't supply a set of tesamorelin users' personal experiences. You cannot judge expected feelings from the fat measurements alone. Approval covers the specific deep belly fat problem in adults who have HIV. General weight loss, slower aging and better thinking lie outside that approval. The longer trial found fat returning inside the belly after treatment stopped [16]. The result cannot promise lasting fat loss after stopping. Tesamorelin raises a hormone that helps body tissue grow. A concern is encouraging growth of an existing cancer. Trials lasting a limited time cannot settle other unwanted tissue growth after years of use. Those concerns need a doctor's assessment of your health and the medicine's safety information. The short healthy-men study found no clear treatment effect on sugar tests [15]. Longer work in adults who have HIV found no concerning average sugar change [16]. Neither finding proves that every person's blood sugar stayed safe. The studies cannot tell you your personal risk of a sugar problem. Tesamorelin breaks the rules in sports that test for these drugs. Bottles sold as supplies for scientists may differ from prescription medicine. The bottle contents, amount of drug and freedom from germs may be uncertain. Tests of prescription medicine cannot establish the quality of those bottles. ## A scan showing less internal fat doesn’t predict total weight loss Tesamorelin trials tested fat changes in adults who have HIV [12][14][16]. [CJC-1295](/cjc-1295) and [sermorelin](/sermorelin) also prompt natural growth hormone release. That shared action doesn't prove the same fat loss with either drug. Each drug needs its own test of the benefit you want. A scan of internal belly fat measures an area through the belly. Tests of liver fat and the weight of other tissue measure different changes. Muscle and bone weight cannot be treated as fat weight. Blood hormone levels add no direct proof that someone lost weight. The [trial comparison](/compare) explains which patients had which changes. A high hormone reading cannot be ranked against a smaller fat area. The largest printed number doesn't tell you which drug improves health most. Your question about weight loss needs a study of weight loss in similar people. ![Tesamorelin research illustration with abstract endocrine signaling motifs](/images/tesamorelin.webp) --- An independent GH-axis measurement review that preserves each study’s units and limits; it is neither a dose calculator nor medical advice.